Infliximab maintenance therapy for fistulizing Crohn's disease.
暂无分享,去创建一个
P. Rutgeerts | M. Kamm | C. Bernstein | J. Korzenik | B. Sands | D. Wolf | S. V. van Deventer | B. Feagan | J. Onken | W. Chey | G. Wild | D. Rachmilewitz | R. Fedorak | S. Travers | B. Lashner | F. Anderson | P. Marsters | M. Blank | D. Wolf
[1] H. Shimada,et al. Seton treatment for perianal Crohn's fistulas , 2004, Surgery Today.
[2] Christopher F. Martin,et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. , 2003, Gastroenterology.
[3] An Carbonez,et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.
[4] G. Marchal,et al. Magnetic Resonance Imaging of the Effects of Infliximab on Perianal Fistulizing Crohn's Disease , 2003, American Journal of Gastroenterology.
[5] Mark Feldman,et al. Sleisenger and Fordtran's gastrointestinal and liver disease , 2012 .
[6] M. Greene,et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. , 2002, Arthritis and rheumatism.
[7] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[8] A. V. van Bodegraven,et al. Endosonographic Evidence of Persistence of Crohn’s Disease-Associated Fistulas After Infliximab Treatment, Irrespective of Clinical Response , 2002, Diseases of the colon and rectum.
[9] W. Sandborn,et al. Diagnosis and Treatment of Perianal Fistulas in Crohn Disease , 2001, Annals of Internal Medicine.
[10] Joseph Keane,et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .
[11] R. Cohen,et al. Anti-TNF therapy and malignancy - a critical review. , 2001, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[12] M. Keighley,et al. Effect of Fecal Diversion Alone on Perianal Crohn's Disease , 2000, World Journal of Surgery.
[13] S. Bickston,et al. The relationship between infliximab treatment and lymphoma in Crohn's disease. , 1999, Gastroenterology.
[14] P. Rutgeerts,et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.
[15] R. Löfberg,et al. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. , 1998, Gastroenterology.
[16] W. Sandborn,et al. Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous Cyclosporine , 1998, American Journal of Gastroenterology.
[17] G. Fick,et al. Azathioprine and 6-Mercaptopurine in Crohn Disease , 1995, Annals of Internal Medicine.
[18] J. Rochon,et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.
[19] I. Guggenmoos‐Holzmann,et al. [Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study]. , 2008, Deutsche medizinische Wochenschrift.
[20] M. Schuster,et al. Metronidazole therapy for Crohn's disease and associated fistulae. , 1984, The American journal of gastroenterology.
[21] B. Pasternack,et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. , 1980, The New England journal of medicine.
[22] D. Franchimont,et al. Crohn's Disease , 1976, The Lancet.
[23] F Kern,et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.